Board Meeting Details

The Board of Directors meeting was held on August 06, 2026, commencing at 11:30 a.m. and concluding at 06:50 p.m.

Agenda Items Approved

1. Unaudited Financial Results (Standalone and Consolidated) for quarter ended June 30, 2026

2. Re-appointment of M/s. Rao Murthy & Associates (Firm Registration No. 000065) as Cost Auditor for FY 2026-27

3. Further investment of up to ₹16 crore in HCG Rajkot Hospitals LLP (wholly owned subsidiary)

Standalone Financial Results (₹ in Lakhs)

Income Statement

  • Total Income: Q1 FY27: ₹3,862; Q4 FY26: ₹3,651; Q1 FY25: ₹3,350; FY26: ₹13,950
  • Revenue from Operations: Q1 FY27: ₹3,752; Q4 FY26: ₹3,484; Q1 FY25: ₹3,259; FY26: ₹13,570
  • Total Expenses: Q1 FY27: ₹3,787; Q4 FY26: ₹3,266; Q1 FY25: ₹3,298; FY26: ₹13,300
  • Profit before tax and exceptional items: Q1 FY27: ₹75; Q4 FY26: ₹386; Q1 FY25: ₹52; FY26: ₹650
  • Exceptional items: Q4 FY26: (₹475); FY26: (₹554)
  • Tax expense: Q1 FY27: ₹19; Q4 FY26: (₹105); Q1 FY25: ₹18; FY26: (₹50)
  • Profit for period: Q1 FY27: ₹56; Q4 FY26: ₹15; Q1 FY25: ₹35; FY26: ₹146
  • Total comprehensive income: Q1 FY27: ₹56; Q4 FY26: ₹14; Q1 FY25: ₹35; FY26: ₹147

Key Metrics

  • Paid-up equity share capital: ₹14,930 lakhs (Face value ₹10 each)
  • Basic EPS (₹): Q1 FY27: 0.37; Q4 FY26: 0.11; Q1 FY25: 0.25; FY26: 1.03
  • Diluted EPS (₹): Q1 FY27: 0.37; Q4 FY26: 0.11; Q1 FY25: 0.24; FY26: 1.03

Consolidated Financial Results (₹ in Lakhs)

Income Statement

  • Total Income: Q1 FY27: ₹7,072; Q4 FY26: ₹6,654; Q1 FY25: ₹6,200; FY26: ₹25,704
  • Revenue from Operations: Q1 FY27: ₹6,934; Q4 FY26: ₹6,503; Q1 FY25: ₹6,118; FY26: ₹25,384
  • Total Expenses: Q1 FY27: ₹6,831; Q4 FY26: ₹6,328; Q1 FY25: ₹6,088; FY26: ₹25,004
  • Profit before share of JV and exceptional items: Q1 FY27: ₹241; Q4 FY26: ₹326; Q1 FY25: ₹112; FY26: ₹700
  • Share of profit of joint venture: Q1 FY27: ₹9; Q4 FY26: ₹5; Q1 FY25: ₹7; FY26: ₹15
  • Exceptional items: Q4 FY26: (₹319); FY26: (₹446)
  • Tax expense: Q1 FY27: ₹86; Q4 FY26: (₹28); Q1 FY25: ₹59; FY26: ₹41
  • Profit for period: Q1 FY27: ₹165; Q4 FY26: ₹40; Q1 FY25: ₹60; FY26: ₹228
  • Total comprehensive income: Q1 FY27: ₹170; Q4 FY26: ₹57; Q1 FY25: ₹62; FY26: ₹273

Attribution

  • Profit attributable to owners: Q1 FY27: ₹138; Q4 FY26: ₹22; Q1 FY25: ₹48; FY26: ₹138
  • Total comprehensive income attributable to owners: Q1 FY27: ₹142; Q4 FY26: ₹43; Q1 FY25: ₹49; FY26: ₹183

Key Metrics

  • Paid-up equity share capital: ₹14,930 lakhs (Face value ₹10 each)
  • Basic EPS (₹): Q1 FY27: 0.92; Q4 FY26: 0.15; Q1 FY25: 0.34; FY26: 0.97
  • Diluted EPS (₹): Q1 FY27: 0.92; Q4 FY26: 0.15; Q1 FY25: 0.33; FY26: 0.96

Exceptional Items Details

Standalone

1. BACC Healthcare divestment: Impairment loss of ₹3,752 lakhs recognized in Q4 FY26 and FY26 based on fair value. Divestment completed on June 29, 2026, to Inviga Healthcare Fund I for ₹3,764 lakhs (₹2,823 lakhs received upfront, ₹941 lakhs receivable within 18 months).

2. HCG Kolkata Cancer Care LLP: Impairment of ₹3,000 lakhs in Q4 FY26 and FY26. Cumulative impairment provision of ₹6,120 lakhs against total investment of ₹13,157 lakhs.

3. HCG Manavata Oncology LLP: Impairment reversal of ₹2,000 lakhs in Q4 FY26 and FY26. Total investment of ₹5,715 lakhs.

4. Labour Code impact: Incremental impact on gratuity (₹640 lakhs) and compensated absences (₹146 lakhs) recognized as exceptional item in FY26.

Consolidated

1. BACC Healthcare divestment: Goodwill impairment of ₹3,191 lakhs recognized in Q4 FY26 and FY26. Gain of ₹296 lakhs recognized in current quarter upon completion of divestment.

2. Labour Code impact: Incremental impact on employee benefit obligations aggregating ₹1,267 lakhs recognized as exceptional item in FY26.

Other Material Disclosures

1. Rights Issue: During FY26, company completed rights issue of 8,294,566 equity shares (face value ₹10) at issue price of ₹512 per share (including securities premium of ₹502), aggregating ₹42,468 lakhs. Share issue expenses of ₹483 lakhs adjusted against securities premium reserve. Entire proceeds utilized in current quarter.

2. Vizag Hospital acquisition: Completed acquisition of additional 34% equity in VHCRPL on April 13, 2026, for ₹15,450 lakhs (initial 51% acquired on October 1, 2024, for ₹20,632 lakhs).

3. ESOP Scheme: HCG ESOS 2026 approved by shareholders on July 8, 2026, with maximum 74,21,455 options. Up to 18,55,364 options (1.24% of diluted equity) approved for Dr. Manish Matteo, Executive Director and CEO.

4. Tax reversal: Income tax expense for Q4 FY26 and FY26 includes reversal of ₹1,820 lakhs relating to earlier years.

5. Segment information: Single operating segment - 'setting up and managing hospitals and medical diagnostic services'.

6. Auditor: Limited review conducted by B S R & Co. LLP (Firm Registration No.: 101248W/W-100022).